CRP and myocardial infarction: Despite significantly decreasing LDL cholesterol and CRP levels and reducing cardiovascular hospitalizations, rosuvastatin failed to reduce the primary outcome (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) or the number of deaths from any other cause [28].